Bioscience Company Presents Preclinical Discovery For Obesity Treatment

Elevai Biosciences, a division of Elevai Labs, Inc. (NASDAQ: ELAB), is making waves in the medical community with its groundbreaking preclinical findings on EL-22, a promising therapeutic for obesity treatment. The company's focus on combining cutting-edge aesthetic medicine development with strategic acquisitions has brought to light the potential of EL-22, especially when used alongside popular GLP-1 receptor agonists. This innovative approach aims to revolutionize obesity treatment by preserving muscle mass while reducing fat mass, a much-needed solution given the rising prevalence of obesity worldwide. $Elevai Labs(ELAB.US)$